Vera Therapeutics to Present at Upcoming Conferences in May 2022
A replay of the event will be available for 30 days and can be accessed by visiting the Investor Calendar section of the Vera Therapeutics website.
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at the following conferences in May, as detailed below:
LifeSci Partners Immunology & Inflammation Symposium (May 10 – 11, 2022)
| Format: | Fireside Chat |
| Date and Time: | Tuesday, May 10, 2022, 2:30-2:55 PM ET |
| Webcast: | A live audio webcast is available at https://bit.ly/3kJMKzy |
H.C. Wainwright Global Investment Conference (May 23 – 26, 2022)
| Format: | Presentation |
| Date and Time: | Wednesday, May 25, 2022, 1:30-2:00 PM ET |
| Webcast: | A live audio webcast is available at https://bit.ly/3OYCZLE |
A replay of the event will be available for 30 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
About Vera Therapeutics
Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
[email protected]
Media Contact:
Kathy Vincent
Greig Communications, Inc.
[email protected]
